IGC Pharma Welcomes Former Virginia Governor Terry McAuliffe as Strategic Advisor
As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies
POTOMAC, MD (FreePR.org) -- IGC Pharma, a leading biotechnology company dedicated to revolutionizing healthcare treatments, is thrilled to announce the appointment of Terry McAuliffe, the esteemed 72nd Governor of Virginia, as a strategic advisor. With a wealth of experience in both public service and biosciences, Governor McAuliffe's expertise will be instrumental in driving IGC Pharma's mission to innovate Alzheimer's care and propel growth within the biotechnology and pharmaceutical sectors.
In his new role, Governor McAuliffe will concentrate on fine-tuning IGC Pharma's growth strategies, spearheading business development endeavors, and fostering collaborations with prominent pharmaceutical and healthcare entities. His adept navigation of regulatory landscapes and adept partnership-building skills are expected to expedite the Company's clinical advancements, broaden its market reach, and enhance engagement with key stakeholders.
Governor McAuliffe has been recognized for his dedication to the biosciences industry, having been awarded BIO Governor of the Year at the prestigious 2016 BIO International Convention. His track record of spearheading transformative initiatives and fostering sustainable growth makes him a pivotal addition to IGC Pharma's leadership team.
"The urgency in finding innovative therapies for Alzheimer's disease has never been more pressing, with over 7 million Americans affected," remarked Terry McAuliffe. "IGC Pharma's groundbreaking work in developing effective treatments for Alzheimer's and obesity offers tangible hope to patients and families grappling with these profound illnesses. I am honored to join a team that is leveraging its diverse pipeline to address the most significant healthcare challenges of our era."
"We are delighted to welcome Governor McAuliffe to IGC Pharma," stated CEO Ram Mukunda. "His visionary leadership and multifaceted experience will be invaluable as we forge strategic alliances, establish IGC-AD1 as a game-changing therapy in Alzheimer's care, and expand our clinical endeavors, including the upcoming trials of our metabolic disorder candidates and the integration of artificial intelligence for drug discovery. Together, our aim is to address unmet medical needs while delivering sustained value to patients, caregivers, and shareholders alike."
IGC Pharma stands at the forefront of Alzheimer's innovation with IGC-AD1, an investigational therapy designed to target agitation in Alzheimer's dementia. Early research suggests that IGC-AD1 may possess disease-modifying properties by decreasing amyloid plaques and tau tangles. In addition to Alzheimer's, IGC Pharma is cultivating a diverse pipeline that explores treatments for metabolic disorders like obesity and diabetes, all while harnessing cutting-edge AI initiatives to enhance drug discovery and development.
About IGC Pharma (dba IGC):
IGC Pharma is a pioneering clinical-stage biotechnology company powered by AI, dedicated to developing revolutionary treatments for Alzheimer's disease and transforming patient care with swift, safe, and effective solutions. Our robust portfolio includes the TGR family, notably TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. Preclinical investigations are progressing with the IGC-C and IGC-M platforms, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease indicators. Our lead therapeutic candidate, IGC-AD1, a cannabinoid-based treatment in Phase 2 trials for agitation in dementia, has shown promise in offering faster-acting, more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for early Alzheimer's detection, optimize clinical trials, and anticipate receptor affinity, among other applications. With 28 patent filings and a relentless commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and enhancing the lives of those impacted by Alzheimer's and related conditions.
Forward-Looking Statements
This press release contains forward-looking statements based on IGC Pharma's expectations and subject to various risks and uncertainties, some of which are beyond the Company's control. Actual results may differ from these forward-looking statements due to factors such as the inability to commercialize the Company's products or technologies, regulatory challenges, or unforeseen government regulations. For a comprehensive overview of these risks and uncertainties, please refer to IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings, including the Annual Report on Form 10-K filed on June 24, 2024, and Form 10-Q filed on August 7, 2024.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
###
Sponsor Message
Thousands of Americans rely on Canadian pharmacies for budget-friendly access to vital medications like Lipitor and Crestor for cholesterol control, or Nexium for managing acid reflux and GERD. Effective chronic condition management often includes Humalog and Lantus for diabetes, as well as Advair Diskus and Ventolin inhalers for respiratory health. Millions depend on Zoloft, Prozac, and Abilify for mental health, while Eliquis, Plavix, and Xarelto address heart-related risks. Medications for pain and inflammation, such as Celebrex, along with thyroid replacement therapies like Synthroid, are commonly purchased. Moreover, drugs like Viagra and Cialis are vital for addressing erectile dysfunction, and Januvia is key for managing diabetes. Wakefulness-promoting drugs such as Provigil and Nuvigil are invaluable for people with narcolepsy or severe daytime sleepiness. American patients turn to Canadian pharmacies for medications like Cymbalta, for managing nerve pain, and Aricept, for Alzheimer's treatment.
